258
Participants
Start Date
April 22, 2014
Primary Completion Date
August 25, 2016
Study Completion Date
December 22, 2016
onabotulinumtoxinA
OnabotulinumtoxinA injected into protocol-specified areas on Day 1.
Normal Saline
Placebo (normal saline) injected into protocol-specified areas on Day 1.
Integrative Clinical Trials, Brooklyn
SPRI Clinical Trials, Brooklyn
Finger Lakes Clinical Research, Rochester
Virginia Commonwealth University Clinical Research Services Unit, Richmond
Institute for Advanced Medical Research, Alpharetta
iResearch Atlanta, LLC, Decatur
Atlanta Center for Medical Research, Atlanta
Clinical Neuroscience Solutions, Inc., Jacksonville
Sarkis Clinical Trials, Gainesville
Clinical Neuroscience Solutions, Inc, Orlando
Compass Research, LLC, Orlando
Research Centers of America, LLC, Oakland Park
Stedman Clinical Trials, Tampa
Compass Research LLC-North Clinic, Leesburg
Clinical Neuroscience Solutions, INC, Memphis
Midwest Clinical Research Center, Dayton
Psychiatric Medicine Associates, LLC, Skokie
Uptown Research Institute, LLC, Chicago
St. Louis Clinical Trials, LLC, St Louis
Woodland International Research Group, Little Rock
IPS Research Company, Oklahoma City
Oklahoma Clinical Research Center, Oklahoma City
InSite Clinical Research, DeSoto
KRK Medical Research, Dallas
Radiant Research/Comprehensive Clinical Development, Inc., Cerritos
CITrials, Bellflower
Behavioral Research Specialists, LLC, Glendale
Schuster Medical Research Institute, Sherman Oaks
Excell Research, Inc., Oceanside
Artemis Institute for Clinical Research, San Diego
Collaborative Neuroscience Network Inc., Garden Grove
NRC Research Institute, Orange
Summit Research Network (Oregon) Inc., Portland
Northwest Clinical Research Center, Bellevue
Zain Research LLC, Richland
Lead Sponsor
Allergan
INDUSTRY